Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, ...

BOSTON--(BUSINESS WIRE)--Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical-stage biotechnology company developing novel tumor necrosis factor superfamily receptor (TNFSR) antagonist ...

Over the past 20 years, a class of anticancer drugs called CD40 agonist antibodies has shown great promise but also induced great disappointment. While such drugs have been effective at activating the ...

Treatment with the investigational CD40 ligand inhibitor frexalimab significantly reduced new MRI lesions in relapsing multiple sclerosis (MS) by week 24, according to data presented at the joint ...

Inflammation in the blood could serve as a new biomarker to help identify patients with advanced pancreatic cancer who won't respond to the immune-stimulating drugs known as CD40 agonists, suggests a ...

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced data from a phase 1 clinical trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic PDAC at ...

A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers. Use of a tissue-free epigenomic circulating tumor DNA (ctDNA) assay for ...

Veronica Paulus is a former STAT intern supported by the Harvard University Institute of Politics. Marissa Russo is a former STAT intern supported by the AAAS Mass Media Science & Engineering ...

This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.